Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivit
Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice. The main aim of the study is to
| Condition(s) | Cataract and IOL Surgery |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice. The main aim of the study is to demonstrate that contrast sensitivity is better with the Clareon PanOptix (CPO) intraocular lens (IOL) compared with the AcrySof PanOptix (APO) IOL 3 months after implantation. |
| Who can participate | Inclusion Criteria: * Patients ≥ 18 years of age * Patients presenting for cataract surgery in routine clinical practice and eligible for multifocal IOL implantation (toric and non-toric) * Patients with grade 2/3 cataract density and comparable visual acuity in both eyes * Patient with a pregnancy test (negative pregnancy test), if applicable * Patient with signed consent to participate in the study * Patient affiliated to a social security scheme or entitled beneficiary Exclusion Criteria: * Children \< 18 years of age * Pregnancy or breast-feeding in progress or planned during the study. * History of anterior (cornea, anterior chamber, sulcus) or posterior (uveal, vitreoretinal) segment pathology, including retinal vascular occlusive disease, retinal detachment or peripheral retinal las |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
| Locations | Paris, Île-de-France Region, France |
| Start date | 2025-10-01 |
| NCT ID | NCT07158177 |
| Official listing | https://clinicaltrials.gov/study/NCT07158177 |